impact factor, citescore
logo
 

Case Reports

 

No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine


1, 2, 3, 4, 5, 6

 

  1. Paediatric Cardiology, New York Medical College, USA.
  2. Paediatric Cardiology, Children’s and Women’s Physicians of Westchester LLP, Norwalk, CT, USA.
  3. Pathology, Johns Hopkins Medicine, Baltimore, MD, USA.
  4. Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA.
  5. Medicine, Division of Rheumatology, New York University School of Medicine, New York, USA.
  6. Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, USA. jill.buyon@nyumc.org

CER10192
2017 Vol.35, N°5
PI 0857, PF 0859
Case Reports

Free to view
(click on article PDF icon to read the article)

PMID: 28598777 [PubMed]

Received: 19/12/2016
Accepted : 28/03/2017
In Press: 06/06/2017
Published: 15/09/2017

Abstract

It is currently recommended that hydroxychloroquine (HCQ) be maintained during pregnancy in patients with systemic lupus erythematosus. Recent data suggest that this Toll-like receptor inhibitor may also reduce the recurrence rate of anti-SSA/Ro associated congenital heart block (CHB). This case report describes a unique situation in which a CHB-afflicted, HCQ-exposed pregnancy was electively terminated. The heart did not reveal any characteristic features of cardiotoxicity, providing further evidence supporting the safety of foetal exposure to HCQ.

Rheumatology Article